Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06872242

Italian PheNotypes Obstructive Sleep Apnea Study

Obstructive Sleep Apnea (OSA) is the most common sleep-related breathing disorder, representing a major socioeconomic burden on healthcare systems worldwide. Studies performed in Europe in the last twenty years showed a very high prevalence and highlighted that the severity of untreated OSA worsens over time. OSA is associated also with an increased risk to develop cardiovascular, cerebrovascular and metabolic diseases. Finally, recent studies reported a very high mortality in untreated OSA patients, including those with mild severity.

Data on European population have been obtained by the "ESADA group" (European Sleep Apnea Database) , a consortium of 25 sleep center across Europe that includes three Italian Research Hospitals. The ESADA showed significant differences between European geographical macrozones in terms of symptoms and complications. However, no data are available for the Italian population in terms of prevalence, clinical presentation and comorbidities.

The present project aims to overcome this limitation by obtaining a more defined picture of OSA in Italy. A cohort study was designed in collaboration with the Sleep Centers endorsed by the Italian Scientific Society of Sleep Medicine (AIMS).

Aims of the present project are to:

1. Assess the distribution different physiological (endotypes) and clinical patterns (phenotypes) of OSA in Italian patients 2. Analyze the association between OSA and co-morbidities 3. implementation of an "Italian database" for long-term follow-up studies.

Methods

* Clinical, sleep study and treatment data will be collected for each patient. A clinical questionnaire will be developed in order to standardize the clinical data collection; to this end a feasibility study will be performed on 100 patients (25 pts for Coordinator/HUB center). * Excessive daytime Sleepiness, Neurocognitive, anxiety/depression screening * A web-based data collection platform will be designed to store pseudo-anonymized individual data.

OUTCOMES

1. Distribution of OSA severity in Italy according to the different classification methods 2. Definition of metabolic, cerebro- and cardiovascular risk factors prevalence associated with OSA in Italian Population 3. Distribution of different physiological and clinical patterns and their association with co-morbidities 4. Definition of a screening/case finding questionnaire for Italian Population 5. Definition of an ongoing cohort of patients that will be followed-up 6. Implementation of an OSA registry that will be shared with Italian Health System or Agencies to designed preventive or early diagnosis interventions to reduce the health impact of the disease.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

ASP Cosenza- PO Beato Angelico, Acri, Italy

Loading trial locations.

About this study

Obstructive Sleep Apnea (OSA) is the most common sleep-related breathing disorder, representing a major socioeconomic burden on healthcare systems worldwide. Studies performed in Europe in the last twenty years showed a very high prevalence and highlighted that the severity of untreated OSA worsens over time. OSA is associated also with an increased risk to develop cardiovascular, cerebrovascular and metabolic diseases. Finally, recent studies reported a very high mortality in untreated OSA patients, including those with mild severity.

Data on European population have been obtained by the "ESADA group" (European Sleep Apnea Database), a consortium of 25 sleep center across Europe that includes three Italian Research Hospitals. The ESADA showed significant differences between European geographical macrozones in terms of symptoms and complications. However, no data are available for the Italian population in terms of prevalence, clinical presentation and comorbidities.

The present project aims to overcome this limitation by obtaining a more defined picture of OSA in Italy. A cohort study was designed in collaboration with the Sleep Centers endorsed by the Italian Scientific Society of Sleep Medicine (AIMS).

Aims of the present project are to:

  • Assess the distribution different physiological (endotypes) and clinical patterns (phenotypes) of OSA in Italian patients
  • Analyze the association between OSA and co-morbidities by taking into account the phenotypes already described in the literature, i.e., ESADA, Icelandic Sleep Cohort, and BAVENO classification;
  • implementation of an "Italian database" for long-term follow-up studies. The project will set an HUB and SPOKE organization that include 4 leading research Sleep Center distributed over the Italian territory in collaboration with the Italian Scientific Society of Sleep Medicine (AIMS) network. AIMS is member of the European Federation of National Sleep Society as well as part of World Sleep Association.

Methods

  • Clinical, sleep study and treatment data will be collected for each patient. A clinical questionnaire will be developed in order to standardize the clinical data collection; to this end a feasibility study will be performed on 100 patients (25 pts for Coordinator/HUB center). Additional clinical tests will include: EKG, Spirometry, ABPM, standard blood chemistry, CPR, TSH reflex, glycemic control assesment, Vitamin D and B12.
  • Excessive daytime Sleepiness, Neurocognitive, anxiety/depression screening will be performed by means of ESS, MOCA and HADS, respectively
  • A web-based data collection platform will be designed to store pseudo-anonymized individual data.

OUTCOMES

  • Distribution of OSA severity in Italy according to the different classification methods (AHI based; hypoxic burden; Icelandic Sleep Cohort, ESADA and BAVENO method)
  • Definition of metabolic, cerebro- and cardiovascular risk factors prevalence associated with OSA in Italian Population
  • Distribution of different physiological and clinical patterns and their association with co-morbidities; analysis of differences with other populations.
  • Definition of a screening/case finding questionnaire for Italian Population
  • Definition of an ongoing cohort of patients that will be followed-up
  • Implementation of an OSA registry that will be shared with Italian Health System or Agencies to designed preventive or early diagnosis interventions to reduce the health impact of the disease.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Suspected Obstructive Sleep Apnea
  • Age 18 years or older

Exclusion criteria

  • Unstable psychiatric disease
  • Limited life expectancy due to illness unrelated to sleep apnoea or other medical conditions which may interfere with the study protocol in the opinion of the investigator

Treatment and study plan

Polysomnography

Diagnostic Test

Polysomnography after enrollment for suspected obstructive sleep apnea

Primary outcomes

  1. Apnea-Hypopnea Index

    Time frame: At enrollment

    Apnea-Hypopnea Index as determined by Polysomnography

  2. Oxygen saturation

    Time frame: At enrollment

    Oxygen saturation as determined by Polysomnography

Study contacts

Contact information is provided by the study sponsor or research team.

Carolina Lombardi, PhD

CONTACT

[email protected]

+3902619111 ext. 2750

Sponsors and collaborators

Lead sponsor

Istituto Auxologico Italiano

Other

Registry information

Acronym: IPNOS

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Mar 12, 2025
Registry last updated
Mar 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.